Rowlandmiller & PARTNERS.ADV Sells 1,613 Shares of Baxter International Inc. (NYSE:BAX)

Rowlandmiller & PARTNERS.ADV reduced its position in Baxter International Inc. (NYSE:BAX) by 28.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,067 shares of the medical instruments supplier’s stock after selling 1,613 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Baxter International were worth $119,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in shares of Baxter International in the third quarter valued at about $38,000. LRI Investments LLC raised its holdings in shares of Baxter International by 60.8% in the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 590 shares in the last quarter. Bruce G. Allen Investments LLC raised its holdings in shares of Baxter International by 247.3% in the fourth quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after acquiring an additional 1,867 shares in the last quarter. CKW Financial Group raised its holdings in shares of Baxter International by 19.3% in the fourth quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock valued at $77,000 after acquiring an additional 425 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Baxter International by 23.2% in the third quarter. Farther Finance Advisors LLC now owns 2,519 shares of the medical instruments supplier’s stock valued at $96,000 after acquiring an additional 475 shares in the last quarter. 90.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BAX shares. StockNews.com downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Friday. Barclays started coverage on shares of Baxter International in a report on Thursday. They issued an “overweight” rating and a $39.00 target price for the company. Citigroup reduced their target price on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Finally, Stifel Nicolaus reduced their target price on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $38.80.

Baxter International Price Performance

Shares of BAX stock opened at $33.87 on Monday. Baxter International Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $44.01. The firm has a market capitalization of $17.29 billion, a price-to-earnings ratio of -26.46, a PEG ratio of 10.62 and a beta of 0.61. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. The stock’s 50-day simple moving average is $30.65 and its 200-day simple moving average is $34.10.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The business had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion. As a group, equities analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a yield of 2.01%. Baxter International’s dividend payout ratio is currently -53.13%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.